Low-dose nivolumab (Opdivo) plus lenalidomide (Revlimid) yielded a promising response with a favorable safety profile in patients with classical Hodgkin lymphoma (cHL), according to a single-arm phase ...

Multiple Posters Highlight the Breadth of Company’s Novel Genetic Medicine and Cell Therapy PlatformsLONDON and NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a ...

Holdin announced the Company will exhibit two posters at the European Society of Gene and Cell Therapy 2025 Annual Congress, which ...

Explore the latest advancements in liquid biopsy for oncology, examining current trends and insights that could shape future ...

Dr. Wang, who also serves as the founding director for research in the Division of Data Science, is leading efforts to create ...

Sales of bioAffinity's CyPath® Lung test for lung cancer reached a new high in Q3 2025, representing a 95% increase over the ...

Researchers believe they have developed the first dedicated blood test to diagnose chronic fatigue syndrome (CFS), also known ...

Scott Soefje, PharmD, MBA, BCOP, discusses how remote patient monitoring and caregiver support enable safe outpatient delivery of bispecific antibodies and antibody-drug conjugates.

DNA blood test identifies chronic fatigue syndrome with 96% accuracy. Early results need larger trials before clinical use.

In this video, Tycel Phillips, MD, discusses initial results of a phase 1b clinical trial focused on treating diffuse large B ...

The ZUMA-24 study showed outpatient axicabtagene ciloleucel (axi-cel) for DLBCL reduced hospitalization and improved safety profiles. CAR T-cell therapy for DLBCL shows promise in outpatient settings, ...